Selected article for: "glargine insulin and insulin sensitivity"
Title: 2015 ACVIM Forum Research Abstract Program
  • Document date: 2015_5_27
    • ID: 3pnuj5ru_297
    Snippet: The primary objective of this study was to evaluate the efficacy and safety of a combination of a short-acting GLP-1 mimetic (Exenatide) with glargine insulin (Protocol A) compared to glargine with a placebo (Protocol B) for the treatment of DM in overweight cats. The effect of treatment protocol A versus B on serum concentrations of specific hormones that play a role in glycemic regulation (insulin and glucagon) or in altering insulin sensitivit.....
    Document: The primary objective of this study was to evaluate the efficacy and safety of a combination of a short-acting GLP-1 mimetic (Exenatide) with glargine insulin (Protocol A) compared to glargine with a placebo (Protocol B) for the treatment of DM in overweight cats. The effect of treatment protocol A versus B on serum concentrations of specific hormones that play a role in glycemic regulation (insulin and glucagon) or in altering insulin sensitivity and resistance (leptin and adiponectin) was also determined.

    Search related documents:
    Co phrase search for related documents
    • DM treatment and insulin sensitivity: 1
    • DM treatment and safety efficacy: 1
    • glargine insulin and glucagon insulin: 1
    • glargine insulin and glycemic regulation: 1
    • glargine insulin and insulin sensitivity: 1
    • glargine insulin and Protocol glargine insulin: 1
    • glargine insulin and safety efficacy: 1, 2, 3, 4
    • glucagon insulin and insulin sensitivity: 1, 2, 3, 4, 5
    • glucagon insulin and safety efficacy: 1, 2
    • glycemic regulation and insulin sensitivity: 1
    • glycemic regulation and Protocol glargine insulin: 1
    • insulin sensitivity and primary objective: 1, 2
    • insulin sensitivity and Protocol glargine insulin: 1
    • insulin sensitivity and resistance insulin sensitivity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • insulin sensitivity and safety efficacy: 1, 2, 3, 4
    • insulin sensitivity and serum concentration: 1, 2
    • primary objective and safety efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • primary objective and serum concentration: 1, 2
    • safety efficacy and serum concentration: 1, 2, 3, 4